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Asp9-Asn (exon 2) and Asn291-Ser (exon 6), in decreased LPL activity and reduced 
HDL-C levels amongst patients with familial combined hyperlipidaemia. We investigated 
the potential influence of these mutations upon serum lipids/lipoproteins amongst the 
representative, homogeneous, adult male population of Caerphilly. 
Methods: 2,316 men were purposely recruited into the Caerphilly Prospective Heart Dis- 
ease Study, when they were aged between 45-59 years, to prospectively screen and 
monitor them for CHD and its risk factors. DNA was available for genotyping on 1,958 
men from the phase 2 collection. We genotype d them for these mutations and the data 
was assessed using non-parametric statistical analyses. 
Results: The T2 (Asp9-Asn) and R2 (Asn291-Ser) alleles denote restriction sites for the 
Taql and Rsal enzymes, respectively. Men possessing the T1 allele had significantly 
raised levels of apo-A1 (131.3 mg/dl vs 124.9 mg/dl, p=0.009), the major surface protein 
activating HDL. Whilst individuals possessing the R2 allele had significantly reduced 
HDL-C levels (0.90 mmol/I vs 1.02 mmol/1, p--O.006) and increased TC/HDL-C ratios 
(6.73 vs 5.84, p=0.043). Interestingly, our cohort did not have any R2R2 homozygotes. 
Conclusions: Our data suggests that the LPL gene influences lipids/ lipoproteins and 
dyslipideemia mongst he UK adult, male population. 
1083-70 Modulation by TGF-Betel  of  Oxldlzed-LDL-Induced 
Upregulat lon of P-Selectln and IGAM-1 and Monocyte 
Adhesion in Human Coronary Endothelial Cells 
Jawahar L. Mehta, Honoiiano Chen, Dayuan Li, University of Arkansas for Medical 
Sciences, Little Rock, Arkansas, Central Arkansas Veterans Healthcare System, Little 
Rock, Arkansas. 
Background: Oxidized-LDL (ox-LDL) upregulates expression of LOX-1, a specialized lec- 
tin-like receptor, on endothelial cells. Uprsgulation of LOX-1 is associated with expression 
of adhesion molecules and monocyte adhesion to endothelial cells. This mechanism may 
relate to the pathogenicity of ox-LDL in atherogenesis. Further, TGF-betal has been postu- 
lated to exert tissue protective and anti-atherogenic effect. We designed this study to inves- 
tigate the role of TGF-betal in ox-LDL-induced expression of adhesion molecules and 
monocyte adhesion to human coronary artery endothelial cells (HCAECs). 
Methods and results: Fifth generation cultured HCAECs were incubated with native-LDL or 
ox-LDL (10-40 mg/ml) for 1-24 hrs. Parallel sets of HCAECs were treated with a specific 
antibody to LOX-1 (10 mg/ml) or to recombinant TGF-betal (2 ng/ml) before incubation 
with ox-LDL (40 mg/ml). Incubation of HCAECs with ox-LDL, but not native-LDL, signifi- 
cantly increased expression P-selectin and ICAM-1 (Western analysis) and monocyte 
adhesion to HCAECs (all P<0.01 vs. n-LDL, n=5). Ox-LDL also decreased active TGF- 
bets1 levels (measured by ELISA) in a time- and concentration-dependent manner 
(P<0.05 vs. control). Antibody to LOX-1 attenuated the reduction in TGF-betal levels 
(P<0.05 vs. ox-LDL alone). Simultaneously, recombinant TGF-betal reduced the expres- 
sion of P-selectin and ICAM-1, as well as monocyte adhesion to HCAECs induced by ox- 
LDL (all P<0.02, n=5). 
Conclusion: This study shows that 1) ox-LDL decreases active TGF-betal levels by activa- 
tion of LOX-1; 2) the reduction in active TGF-betal may be the basis of ox-LDL-mediated 
upregulation of P-selsctin and ICAM-1 expression and monocyte adhesion to HCAECs. 
1083-71 A Cholesteryl Ester Transfer Protein Inhibitor Increased 
In Vlvo Synthatlc Rates and Liver mRNA Levels of 
Apol lpoprofein A-I 
Eiso Shimoji, Bo Zhano, Ping Fan, Keijiro Saku, Fukuoka Universi~ Fukuoka, Japan. 
Background: Patients with cholesteryl ester transfer protein (CETP) deficiency have 
increased HDL-C levels, and the inhibition of CETP activity has been shown to increase 
apolipoprotein (ape) A-I levels and suppress the progression of atheroosclerosis n choles- 
terol-fed rabbits. To clarify the mechanism by which CETP inhibition increases serum apo 
A-I levels, the effects of a CETP inhibitor, JTT-705, on in vivo apo A°I kinetics and tissue 
apo A-I gene expression were investigated. 
Methods: Japanese White rabbits were randomly fed a diet with (n=8, treated) or without 
(n=10, controls) 0.75% J'l-r-705 (Japan Tabasco Inc.) for 7 mo. CETP activities and 
serum levels of apo A-I and HDL-C levels were measured. Apo A-I kinetics were per- 
formed by injecting radioiodinated apo A-I, which was freshly prepared by the guanidine 
HCI method. Apo A-I mRNA levels in the liver and intestine were quantified by SYBR 
real-time RT-PCR. 
Results: JTT-705 inhibited 32.0% of the CETP activity and increased (p<0.05) the serum 
levels of HDL-C and apo A-I (66.5 ± 13.7 vs. 42.9 ± 6.2 mg/dL). Treated rabbits had a 
greater (p<O.05) synthetic rate (SR) of HDL-apo A-I than control rabbits (13.1 ± 2.6 vs. 
10.0 ± 1.9 mg/Kg/day), while the fractional catabolic rates in the two groups were similar 
(0.47 ± 0.10/day and 0.52 ± 0.09/day). JTT-705 increased apo A-I mRNA levels In the 
liver but not In Inteetlne (Figure). 
Conclusion: Increased SR and liver gene expression of apo A-I contribute to the 
increased serum apo A-I levels induced by CETP inhibition. 
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1083-95 Mutation In the Promoter Region of the Hepatic Lipase 
Gene Correlates With Dysl ipidemia In Type 2 Diabetes 
RaJ K. Mattu. Edward W. Needham, Jasper Trevelyan, Dimitri J. Richter, Maria A. 
Adiseshiah, Mauro Lencioni, Shane Gieewarsingh, D. John Befferidge, University 
Hospitals Coventry & Warwickshire &University of Warwick, Coventry, United Kingdom, 
University College London Medical School, London, United Kingdom. 
Background: Cardiovascular disease remains the major cause of morbidity and mortality 
amongst ype II diabetics. The total coronary heart disease risk of these patients is much 
higher than for non-diabetics at every level of given risk factor, such as dyslipidaemia. 
About 40% of diabetics have hypertriglyceridaemia (HTG) and reduced high-density Iipo- 
protein cholesterol (HDL-C). Hepatic lipase (HL) is a key enzyme in the hydrolysis of trig- 
lycerides in the core of remnant lipoprotein particles and facilitates activation of HDL 
particles. It therefore influences serum triglycedde and HDL-C levels and may be an 
important determinant of the dyslipidaemia observed amongst diabetics. A C-514-T 
mutation involving the promoter egion of the HL gene associates with reduced HL activ- 
ity and increased HDL2 levels, hence we examined whether this mutation related 10 
serum lipids amongst ype II diabetics. 
Methods: We recruited 386 consecutive patients attending the diabetes clinic. All cardio- 
vascular risk factors were characterised and studied once the patient's diabetic control 
had become satisfactory. Patient lipids were analysed without lipid modifying drugs. 
Patients were genotyped using the polymerase chain reaction. 
Results: Triglyceride levels were significantly higher (3.25 vs 2.53 retool/I, p=0.03) 
amongst diabetics possessing the TT genofype. Furthermore, subjects possessing the 
C-514-T promoter mutation had a 78% increased risk of being in the highest tertile of the 
total cholesterol/HDL-C ratio distribution, O.R. 1.78 (1.00-3.17, p=0.048). 
Conclusions: Mutation of the promoter egion of the hepatic lipase gene may predispose 
type II diabetic patients to a deleterious lipid profile and possibly influence their coronary 
heart disease risk. 
1083-96 Increasing Testosterone Lowers High Density 
Lipoproteln Cholesterol by Decreasing Apol lpoproteins 
AI and All 
John A. Morrison, Dennis L. Sprscher, Bruce A. Barton, Children's Hospital Medical 
Center, Cincinnati, Ohio, Maryland Research Institute, Baltimore, Maryland. 
Background: During puberty, high density lipoprotein cholesterol (HDL-C) and its major 
associated apolipoproteins (apo), AI and All, decrease markedly in males, but not in 
females, resulting in the recognized sex differences in lipid profiles and attendant risk to 
coronary heart disease. The timing of the changes has implicated sex steroid hormones, 
especially free testosterone (T) in the changes. Previous studies of pubertal males have 
been limited by small samples, cross sectional designs, or longitudinal designs using 
only two points in time, design elements that restrict he power of the studies. 
Methods: To explicate the role of free T in the pubertal changes in adolescent male lipids 
we followed 251 black and 283 white males, ages 10-15 yrs at enrollment, for three 
years. We measured lipid profiles, free testosterone (T), estradiol, and body mass index 
(BMI = kg/m2) every 6 months and apo AI and All annually. 
Results: Controlling for pubertal stage, black males had higher HDL-C, apoAI, (all 
p<.001), and apoAII (p=.06) than white males. With advancing pubertal stage, HDL-C, 
apoAI and All decreased in both black and white boys. Longitudinal, multivariate analy- 
ses (General Estimating Equations) showed that increasing free T associated with 
decreasing HDL-C, apo AI and All (all p<.01), but did not affect the ratio of HDL-C to 
apoAI and All. When apoAI and All were entered into the model for changes in HDL-C as 
predictors, they contnbuted significantly to decreases in HDL-C. At this point, however, 
free T dropped out of the model, suggesting that the effects of free T on HDL-C are medi- 
ated through apoAI and All concentrations. Increasing BMI associated with lower HDL-C 
and HDL-C/(apoAI and All) ratios but did not associate with changes in apoAI. Estrediol 
was not associated with changes in HDL-C, apo AI or All. 
Conclusions: During puberty, increasing T appears to contribute to lower HDL-C by low- 
ering the apolipoproteins (apoAI and All) available to these particles, not by altering the 
amount of lipid associated with these protein moieties. 
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1084-90 Ezatimlbe Co-Administered With Slmvastatin in 668 
Patients With Primary Hyperch01esterolemia 
Michael Davidson, Thomas McGarry, Robed Battis, Lorenzo Melani, Leslie Lipka, 
Alexandre LeBeaut, Ramachandrsn Suresh, Steven Sun, Enrico Veltri, for the Ezetimibe 
Study Group, Chicago Center for Cardiovascular Research, Chicago, Illinois, Oklahoma 
Foundation for Clinical Research, Oklahoma Ci~ Oklahoma. 
Background: This Phase III, randomized, double-blind, placebo-controlled study evalu- 
ated the efficacy and safety of ezetimibe (EZE) administered with simvastatin (SIM) in pts 
with primary hyparcholesterolemia. 
Methods: After dietary stabilization (NCEP Step 1 or stricter diet), a 2-12 wk screening/ 
washout period and a 4-wk, single-blind, PBO lead-in period, 668 pts with baseline LDL- 
C _>145 mg/dl to -<250 rag/all and TG -<350 rag/all were randomized to 1 of the following 
administered aily for 12 consecutive wks: EZE 10 rag; SIM 10, 20, 40 or 80 rag; EZE mg 
JACC March 6, 2002 ABSTRACTS - Hypertension, Vascular Disease, and Prevention 227A 
+ $1M 10, 20, 40 or 80; or PBO. Primary efficacy endpoint was % reduction from baseline 
to endpoint in direct LDL-C for pooled EZE + SIM vs pooled SIM alone. 
Results: Table shows mean % change from baseline to endpoint. 
Treatment Direct LDL-C HDL-C TG 
PBO (n=70) -1.3 +0.9 +2.4 
EZE 10 mg (n=61) -18.1 +5.1 -6.3 
Pooled SIM (n=263) -36.1 +6.9 -16.6 
Pooled EZE + SIM (n=274) -49.9* +9.3" -24.1" 
*/~_0.03 for pooled EZE+SiM vs SIM 
EZE + SIM significantly improved LDL-C, HDL-C and TG compared to SIM alone 
(P<0.01). EZE provided an added 13.8% LDL-C reduction, 2.4% HDL-C increase and 
7.5% TG reduction compared to pooled SIM alone. EZE + SIM provided LDL-C reduc- 
tions of 44-57%, TG reductions of 20-28% and HDL-C increases of 8-11% depending on 
the dose. EZE 10 mg + SIM 10 mg and SIM 80 mg alone each provided 44% LDL-C 
reduction. EZE + SIM was well tolerated, with a safety profile similar to PBO. 
Conclusion; When co-administered with SIM, EZE provided significant incremental 
reductions in LDL-C and TG, as well as increases in HDL-C. The co-administration of 
EZE and SIM offers a highly efficacious new treatment approach to pts with hypercholes- 
terolemia. 
1084-91 Ezetimibe Co-Administered With Atorvastatin in 628 
Patients With Primary Hypercholesterolemia 
Christie Ballantvne. John Houri, Alberto Notarbartolo, Lorenzo Melani, Leslie Lipka, 
Alexandre LeBeaut, Ramachandran Suresh, Steven Sun, Enrico Vettri, for the Ezetimibe 
Study Group, Bay/or College of Medicine, Houston, Texas, Radiant Research, Stuart, 
Florida. 
Background: Efficacy and safety of ezetimibe (EZE) administered with atorvastatin 
(ATV) in pts with primary hypercholesterolemia were assessed in a Phase III, multicenter, 
randomized, double-blind, placebo-controlled study. 
Methods: After dietary stabilization on a NCEP Step I or stricter diet, a 2-12-wk screen- 
ing/washout period and a 4-wk, single-blind, PBO lead-in period, 626 pts with baseline 
LDL-C >_145 to _<250 mg/dl + TG _<350 mg/dl were randomized to 1 of the following 
administered daily for 12 consecutive wks: EZE 10 mg; ATV 10, 20, 40 or 80 mg; EZE 10 
mg + ATV 10, 20, 40 or 80 rag; or PBO. Primary efficacy endpoint was % reduction from 
baseline to endpoint in direct LDL-C for pooled EZE + ATV vs pooled ATV alone. 
Results: EZE + ATV was well tolerated, with a safety profile similar to ATV alone and to 
PBO. Table shows mean % chan~e from baseline to endpoint. 
Treatment Direct LDL-C HDL-C TG 
PBO (n=60) 5.9 3.7 4.4 
EZE 10 mg (n=65) -18.4 4.2 -3.4 
Pooled ATV (n=248) -42.4 4.3 -21.5 
Pooled EZE + ATV (n=255) -54.5* 7.3* -29.5* 
*,°<0.01 for pooled EZE+ATV vs ATV 
EZE + ATV significantly improved LDL-C, HDL-C and TG compared to ATV (P<0.01). 
EZE provided an added 12.1% LDL-C reduction, 3.0% HDL-C increase and an added 
8.0% TG reduction vs pooled ATV. EZE + ATV provided LDL-C reductions of 50-60%, TG 
reductions of 26-35% and HDL increases of 4.6-9.2% depending on the dose. LDL-C 
reduction with EZE 10 mg + ATV 10 mg (50%) and ATV 80 mg alone (51%) was similar. 
Conclusion: When co-administered with ATV, EZE provided significant incremental 
reductions in LDL-C and TG and increases in HDL-C. Co-administration of EZE and ATV 
offers a highly efficacious new treatment option for pts with hypercholesterolemia. 
1084-92 Ezetimibe Significantly Reduces Low-Density 
Lipoprotein Cholesterol in Homozygous Familial 
Hypercholesterolemia 
Claude Gagne, Daniel Gaudet. Eric Bruckert, Damien Ponsonnet, Leslie Lipka, 
Alexandre LeBeaut, Ramachandran Suresh, Paula Abreu, Enrico Veltri, for the Ezetimibe 
Study Group, Chul du Chuq, Ste-Foy, Quebec, Canada, Centre Hospitalier de la 
Sagamie - Clinique des Maladies Lipidiques, Chicoutimi, Quebec, Canada. 
Background: Current pharmacological agents for treatment of homozygous familial 
hypercholesterolemia (HoFH) have limited efficacy. We evaluated the efficacy, safety and 
tolerability of ezetimibe (EZE), a novel selective cholesterol absorption inhibitor, in HoFH 
pts already taking atorvastatin (A) or simvastatin (S). 
Methods: Fifty HoFH pts on diet and open-label 40 mg QD (A) or (S), with (n=26) or with- 
out (n=25) concomitant LDL apheresis, were randomized (double blind) to f of 3 daily 12- 
week treatments 1) A or S 60 rag, 2) EZE 10 mg+ A or S 40 rag, or 3) EZE 10 rag+ A or 
S 80 mg, The primary comparison was mean % change in LDL-C from baseline to end- 
point for the group receiving statins alone (Statin-80) vs the group receiving EZE + A or S 
at either dose (EZE+Statin-40/80). Mean % change in LDL-C for the group randomized 
to EZE + A or S 80 mg (EZE+Statin-80) was also compared to Statin-80. 
Results: The table shows least square mean LDL-C concentrations. 
Treatment LDL-C (mg/dl) % Change 
Baseline Endpoint (± SE) 
Statin 80 (n=17) 339 319 -6.7 ± 4.2 
EZE+Statin 40/80 (n=33) 313 247 -20.7 ± 3.2* 
EZE+Statin 80 (n=17) 273 196 -27.5 ± 3.5* 
*P < 0.01 vs. Statin-80 group 
Similar and significant LDL-C reductions were observed for the subset of pts who had a 
genotypic diagnosis of HoFH (n=32). No significant between-group differences were 
observed for HDL-C or TG. EZE was well tolerated as determined by safety laboratory, 
adverse event, and drug discontinuation assessments. 
Conclusion: EZE + A or S produced clinically important LDL-C lowering compared to 
best therapy with A and S in pts with HoFH. EZE provides a new, complementary phar- 
macological approach to this high-risk population. 
1084-93 Does Cholesterol and/or Fat Intake Affect Plasma Lipid 
Efficacy of Ezet imibe? 
Carlos Duiovne. Jolene Held, Leslie Lipka, Alexandre LeBeaut, Ramachandran Suresh, 
Enrico Veltd, for the Ezetimibe Study Group, Kansas Foundation for Clinical 
Pharmacology - Radiant Research, Kansas City, Kansas, Professional Nutrition 
Systems, Westwood, Kansas. 
Objective: To assess effect of degree of dietary saturated fat and cholesterol restriction 
on efficacy of ezetimibe (EZE), a new selective cholesterol absorption inhibitor, in 1719 
patients with primary hyperchelesterolemia. 
Methods: After 6-8 weeks instruction of NCEP Step I or stricter diet during the single- 
blind PBO lead-in, patients with plasma LDL-C 130-250 mg/dt and TG <_350 mg/dl were 
randomized 3:1 to EZE 10 mg/d or PBO for 12 weeks in 2 identically designed Phase III, 
double-blind studies. Data from these 2 studies were pooled for analysis. Primary end- 
point was % reduction of direct LDL-C from baseline to endpoint. Diet compliance was 
assessed every 2-6 weeks at a centralized center by computer analysis of 3-day food- 
intake records. A RISCC (Ratio of Ingeste d Saturated Fat and Cholesterol over Calories) 
score was used to quantitate all fat-related diet components and to compare diets 
between treatments. RISCC=(1.01[saturated fat in g] + 0.05[cholesterol in mg]) + (total 
Kcal/1000). 
Results: Of 1,719 patients (831 men, 888 women; ages 18-86 y), 1286 were randomized 
to EZE and 431 to PBO. Baseline characteristics were comparable between groups. The 
% change (mean ± SEM) in plasma lipid from baseline to endpoint was used to compare 
st EZE and PBO patients in the 1 quartile (lowest) and 4 th quartile (highest) of RISCC val- 
ues (-<13, and ->20) and dietary cholesterol (<_124, and ->250 rag) at baseline. For EZE 
patients, % LDL-C reduction was -19 + 0.6 and -19 _+ 0.6 for patients in the 4 th quartile of 
RISCC (n=353) or cholesterol (n=319), respectively, vs -16 ¢ 0.6 and -17 _+ 0.6 for 
patients in the 1 st quartile of RISCC (n=335) or cholesterol (n=300), respectively. For 
+ th PBO, % LDL-C reduction was -1+ 1 and -0.1 _ 1 for patients in the 4 quartile of RISCC 
(n=109) or cholesterol (n=95), respectively, vs -0.5 _+ 1 and 0.1 _+ 1 for patients in the 1 st 
quartile of RISCC (n=114) or cholesterol (n=115), respectively. The % change LDL-C in 
the 1st and 4th quartites was similar for EZE vs PBO.Conclusions: LDL-C Iowedeg 
attributable to EZE for the lowest and highest quartiles of cholesterol or fat intake did not 
differ significantly. 
1084-94 Atazanavir Plus Saquinavir Once Daily: Favorable 
Effects on Lipid Profiles in Patients Failing Prior 
Protease Inhibitor Therapy (Trial AI424-009) 
David W. Haas, Carlos Zala, Shannon Schrader, Alexandra Thiry, Rachel McGovern, 
Steven Schnittman. Vanderbilt University Medical Center, Nashville, Tennessee. 
Background: Currently approved RIV-1 protease inhibitors (PIs) may increase risk for 
CV events by altering lipid metabolism. Atazanavir (BMS-232632) is a once-daily PI that 
rapidly and durably suppresses HIV RNA and increases CD4. Atazanavir does not 
increase total cholesterol (TC), low-density lipoprotein cholesterol (LDL), or trigtycaride 
(TG) levels in antiretroviral-nai've subjects compared with prompt, marked, and sustained 
elevations with current PIs. Atazanavir and saquinavir have complementary resistance 
profiles and favorable PK interactions allowing for once-daily dosing of the combination. 
This protocol evaluated the safety, tolerability, and efficacy of dual PI therapy with ataza- 
navir (400 or 606 mg qd)/saquinavir (1,200 mg qd) or ritonavir (400 mg bid)/saquinavir 
(400 mg bid) + 2 NRTIs after virologic failure on a PI regimen. 
Methods: Randomized, active-controlled, blinded study in 85 adults with HIV RNA 
1,000-100,000 c/mL and CD4 -> 100 cells/mm 3, 
Results: Wk 24, Observed Data 
Atazanavir/saquinavir once daily Ritonavir/saquinavir 
twice daily 
400 mo (n=~4) 600 me (n=28~ 400 mo fn=231 
Median baseline, mg/dL (mean % change from baseline, n) 
TG 223 (-23, 15) 177 (-21, 13) 191 (90, 8) 
TC 181 (-1,27) 199 (-9, 20) 202 (10, 13) 
Mean change from baseline (SE, n) 
HIV RNA (log10 c/mL) -1.26 (0.20, 29) -1.17 (0.20, 22) -1.50 (0.31, 13) 
CD4 (calls/mm 3) 55 (17, 29) 67 (18, 22) 98 (25, 13) 
Updated results to wk 48 will be presented. Conclusion: In subjects failing a prior PI reg- 
imen, atazanavidsaquinavir lowered TC, LDL, and TG levels from baseline, whereas 
ritonavir/saquinavir produced substantial increases. Atazanavir/saquinavir was safe and 
well tolerated and showed significant antiviral effect at wk 24. The ability to improve 
serum lipid profiles in PI-experienced subjects suggests that atazanavir educes risk fac- 
tors for CV events in this population. 
